San Francisco, CA—The immunotherapy combination of nivolumab (Opdivo) and ipilimumab (Yervoy) provides durable clinical benefit in patients with previously treated DNA mismatch repair–deficient (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer (CRC).
In the United States, colorectal cancer (CRC) is the fourth most common malignancy, with 134,490 new cases and 49,190 deaths estimated in 2016.1 Among these patients, 25% present with advanced disease at diagnosis, and nearly 50% will eventually develop metastatic disease.2 Survival rates for metastatic CRC (mCRC) have been improving, [ Read More ]
Advances in molecular pathology have allowed for the widespread use of sequencing technologies to improve our ability to better understand the biology of each individual patient’s cancer. This allows for the personalization of treatment strategies depending on the molecular profile of the cancer. In colorectal cancer (CRC), mutations in KRAS [ Read More ]
According to the American Cancer Society, colorectal cancer is the third most common cancer in men and women, and the second leading cause of cancer deaths in the United States.1 An estimated 132,700 new cases of, and 49,700 deaths from, colorectal cancer are expected to occur in 2015. For patients [ Read More ]
Although it affects 2 distinct anatomical sites, colorectal cancer is often regarded as a single entity, and treatment plans for colon cancer and rectal cancer are quite similar.1,2 Cases of colorectal cancer comprise more than 8% of newly diagnosed cancer cases and nearly 9% of all cancer deaths in the [ Read More ]
Dr Finnberg is an Assistant Professor at Penn State Hershey Cancer Institute. He received his PhD degree from Karolinska Institutet in Stockholm, Sweden, and has worked extensively to characterize the role of apoptosis in tissue toxicity to conventional and targeted cancer therapeutics. Dr Finnberg’s current research focuses on understanding tissue [ Read More ]
Key Points Although RAS mutations at glycine-12 and glycine-13 are adjacent, identical substitutions at these positions (eg, G12S vs G13S) lead to very different levels of RAS activation The central clinical question remains unanswered: will a patient with metastatic colorectal cancer harboring a KRAS G13D mutation benefit from anti-EGFR therapy? [ Read More ]